Senzime Strengthens U.S. Operations with New Leadership Appointments
Rhea-AI Summary
Senzime (OTCQX:SNZZF) announced senior U.S. leadership changes to strengthen commercial and clinical operations. Josi Wood joins as Vice President of U.S. Sales on May 11, 2026, and Jen Sanders is promoted to Vice President of Clinical and Medical Affairs effective May 1, 2026. G.W. Hamilton moves from President of Senzime Inc. to General Manager of U.S. operations.
The appointments aim to scale U.S. commercial execution and deepen clinical leadership as Senzime advances its perioperative patient-safety offerings.
Positive
- New VP U.S. Sales hire effective May 11, 2026
- Promotion of VP Clinical and Medical Affairs effective May 1, 2026
- Dedicated General Manager for U.S. operations to focus execution
Negative
- President of Senzime Inc. leaves Global Executive Leadership Team
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, SE / ACCESS Newswire / April 29, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB today announced new appointments to its Global Executive Leadership Team, including the recruitment of a new Vice President of U.S. Sales and the appointment of a Vice President of Clinical and Medical Affairs.
Josi Wood, MBA, has been recruited to strengthen the company's U.S. commercial operations as Vice President of U.S. Sales, assuming a newly created leadership role within Senzime. Josi is an accomplished commercial leader with 25 years of experience building and scaling sales organizations in hospital and perioperative care environments. She began her career in product development at Johnson & Johnson Synthes transitioning in 2007 to sales and leadership positions at Monaghan Medical, an industry leader in respiratory care. Over the last seven years, Josi has successfully led U.S. sales teams that received multiple recognitions including Division of the Year, while also coaching and mentoring several Territory Managers who were named Sales Professionals of the Year. Josi resides in Kansas City and joins Senzime on May 11, 2026.
Jen Sanders, RN, BSN, has been promoted to Vice President of Clinical and Medical Affairs in recognition of her outstanding leadership in building Senzime's best-in-class Medical Affairs function and clinical organization. Jen joined Senzime in 2021 as a Clinical Product Specialist and has rapidly advanced through several clinical leadership roles. In early 2025, she assumed responsibility as Executive Director of Clinical and Medical Affairs. Jen is a registered ICU nurse and assumes her new position on May 1, 2026.
"Welcoming these two exceptional leaders to Senzime's global leadership team marks another important step in our growth journey. Josi Wood brings outstanding commercial leadership and deep market experience, and I am delighted to welcome her as we continue to execute our U.S. growth strategy. Jen Sanders has already demonstrated remarkable clinical leadership and strategic capability, and I am equally pleased to welcome Jen to the executive management team. Together, they will play key roles as we continue to scale our business and lead the shift toward safer anesthesia worldwide," commented Philip Siberg, CEO of Senzime.
G.W. Hamilton, who has served as President of Senzime Inc. since 2023, transitions simultaneously to a new role as General Manager of U.S. operations. He leaves the Global Executive Leadership Team and assumes responsibility in ensuring an efficient U.S. operating organization supporting Senzime's continued growth.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
About Senzime
Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.
Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.
Image Attachments
SOURCE: Senzime
View the original press release on ACCESS Newswire